checkAd

    DGAP-News  321  0 Kommentare Epigenomics AG: Journal of Molecular Diagnosis & Therapy publishes review of blood-based screening test Epi proColon(R) 2.0 CE - Seite 3





     














    14.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de




























    Language: English
    Company: Epigenomics AG
    Geneststraße 5
    10829 Berlin
    Germany
    Phone: +49 30 24345-0
    Fax: +49 30 24345-555
    E-mail: ir@epigenomics.com
    Internet: www.epigenomics.com
    ISIN: DE000A11QW50
    WKN: A11QW5
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange





     
    End of News DGAP News Service


    Lesen Sie auch



    544217  14.02.2017 




    Seite 3 von 3




    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    DGAP-News Epigenomics AG: Journal of Molecular Diagnosis & Therapy publishes review of blood-based screening test Epi proColon(R) 2.0 CE - Seite 3 DGAP-News: Epigenomics AG / Key word(s): Study Epigenomics AG: Journal of Molecular Diagnosis & Therapy publishes review of blood-based screening test Epi proColon(R) 2.0 CE 14.02.2017 / 09:45 The issuer is solely responsible for the content of …